EpiStem Holdings Plc reaffirmed earnings guidance for the year ended June 30, 2013. In its trading statement dated 1 August 2013, the company advised shareholders that it was in discussions with Becton Dickinson for an expansion of the supply and distribution agreement of its TB test which, if successful, would lead to additional revenues for the year ended 30 June 2013 of £1.0 million to £1.2 million being recognized. The company advises that the discussions with Becton Dickinson have not been successfully concluded and the supply and distribution agreement originally entered into in August 2012 has been terminated.

The previous guidance for the results for the year ended 30 June 2013 of revenues of £5.4 million and a loss after tax of £1.2 million remains unchanged.